3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Glioblastoma
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Gliosarcoma
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Paclitaxel
37
Carboplatin
28
pembrolizumab
19
Surveys and Questionnaires
11
temsirolimus
10
Radiotherapy
10
Cisplatin
10
Doxorubicin
9
Bevacizumab
9
lenvatinib
8
Docetaxel
8
Nivolumab
7
Metformin
7
Gemcitabine
7
Early Intervention, Educational
7
Counseling
7
Sirolimus
6
Radiation
6
Megestrol Acetate
6
Indocyanine Green
6
olaparib
5
Topotecan
5
Therapeutics
5
Psychiatric Rehabilitation
5
Methods
5
Letrozole
5
Ipilimumab
5
Chemotherapy, Adjuvant
5
ridaforolimus
4
Trastuzumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Endometrial Neoplasms
×
tinostamustine
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts